Abstract
Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis and whether previously reported genes significantly associated with brain metastases and the epithelial-mesenchymal transition (EMT) were reproducible and consistent in our dataset. Sixteen pair-matched samples from primary breast cancers and brain metastases diagnosed were collected from the Japan Clinical Oncology Group Breast Cancer Study Group. Gene expression profiles for immune-, brain metastases-, and EMT-related genes were compared between primary breast cancers and brain metastases. Potential therapeutic target genes of 41 FDA-approved or under-investigation agents for brain metastases were explored. Immune-related signatures exhibited significantly lower gene expression in brain metastases than in primary breast cancers. No significant differences were detected for the majority of genes associated with brain metastases and EMT in the two groups. Among 41 therapeutic target candidates, VEGFA and DNMT3A demonstrated significantly higher gene expression in brain metastases. We found that distinct patterns of gene expression exist between primary breast cancers and brain metastases. Further studies are needed to explore whether these distinct expression profiles derive from or underlie disease status and compare these features between metastases to the brain and other sites.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Journal | Scientific reports |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Sep 16 2019 |
Fingerprint
ASJC Scopus subject areas
- General
Cite this
Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples. / Iwamoto, Takayuki; Niikura, Naoki; Ogiya, Rin; Yasojima, Hiroyuki; Watanabe, Ken Ichi; Kanbayashi, Chizuko; Tsuneizumi, Michiko; Matsui, Akira; Fujisawa, Tomomi; Iwasa, Tsutomu; Shien, Tadahiko; Saji, Shigehira; Masuda, Norikazu; Iwata, Hiroji.
In: Scientific reports, Vol. 9, No. 1, 16.09.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples
AU - Iwamoto, Takayuki
AU - Niikura, Naoki
AU - Ogiya, Rin
AU - Yasojima, Hiroyuki
AU - Watanabe, Ken Ichi
AU - Kanbayashi, Chizuko
AU - Tsuneizumi, Michiko
AU - Matsui, Akira
AU - Fujisawa, Tomomi
AU - Iwasa, Tsutomu
AU - Shien, Tadahiko
AU - Saji, Shigehira
AU - Masuda, Norikazu
AU - Iwata, Hiroji
PY - 2019/9/16
Y1 - 2019/9/16
N2 - Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis and whether previously reported genes significantly associated with brain metastases and the epithelial-mesenchymal transition (EMT) were reproducible and consistent in our dataset. Sixteen pair-matched samples from primary breast cancers and brain metastases diagnosed were collected from the Japan Clinical Oncology Group Breast Cancer Study Group. Gene expression profiles for immune-, brain metastases-, and EMT-related genes were compared between primary breast cancers and brain metastases. Potential therapeutic target genes of 41 FDA-approved or under-investigation agents for brain metastases were explored. Immune-related signatures exhibited significantly lower gene expression in brain metastases than in primary breast cancers. No significant differences were detected for the majority of genes associated with brain metastases and EMT in the two groups. Among 41 therapeutic target candidates, VEGFA and DNMT3A demonstrated significantly higher gene expression in brain metastases. We found that distinct patterns of gene expression exist between primary breast cancers and brain metastases. Further studies are needed to explore whether these distinct expression profiles derive from or underlie disease status and compare these features between metastases to the brain and other sites.
AB - Our objectives were to determine whether clinic-pathological markers and immune-related gene signatures in breast cancer exhibit any change upon brain metastasis and whether previously reported genes significantly associated with brain metastases and the epithelial-mesenchymal transition (EMT) were reproducible and consistent in our dataset. Sixteen pair-matched samples from primary breast cancers and brain metastases diagnosed were collected from the Japan Clinical Oncology Group Breast Cancer Study Group. Gene expression profiles for immune-, brain metastases-, and EMT-related genes were compared between primary breast cancers and brain metastases. Potential therapeutic target genes of 41 FDA-approved or under-investigation agents for brain metastases were explored. Immune-related signatures exhibited significantly lower gene expression in brain metastases than in primary breast cancers. No significant differences were detected for the majority of genes associated with brain metastases and EMT in the two groups. Among 41 therapeutic target candidates, VEGFA and DNMT3A demonstrated significantly higher gene expression in brain metastases. We found that distinct patterns of gene expression exist between primary breast cancers and brain metastases. Further studies are needed to explore whether these distinct expression profiles derive from or underlie disease status and compare these features between metastases to the brain and other sites.
UR - http://www.scopus.com/inward/record.url?scp=85072295796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072295796&partnerID=8YFLogxK
U2 - 10.1038/s41598-019-50099-y
DO - 10.1038/s41598-019-50099-y
M3 - Article
C2 - 31527824
AN - SCOPUS:85072295796
VL - 9
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
ER -